MEG3 and neoplasm: While TDRG1 promotes tumor progression and immune evasion by upregulating VEGF-A levels, thereby potentially contributing to endothelial anergy and impaired immune cell infiltration, MEG3 acts as a tumor suppressor by repressing VEGF expression under stress conditions such as hyperglycemia.